European Polyp Surveillance Trial

NCT ID: NCT02319928

Last Updated: 2021-01-12

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 20000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2028-12-31

Brief Summary

This protocol describes the epos (ancient greek (Επος) for "story") of a group of related clinical trials aiming at addressing one of the most important unsolved challenges in the prevention of colorectal cancer (one of our major cancer killers); the surveillance of patients with premalignant polyps in the large bowel.

This project is timely because large scale colorectal cancer screening programmes are currently rolled out in most Western countries. These programmes are diagnosing large numbers of individuals with premalignant polyps (adenomas and serrated polyps). This creates both a diagnostic and resource dilemma, because the optimal surveillance strategy for these individuals to reduce future cancer risk is currently unknown..

The EPoS trials will randomize or register more than 20,000 individuals in different European countries to different surveillance colonoscopy intervals to disentangle the most effective and cost-effective surveillance strategy for the population. Subjects will be randomized according to their presenting polyp chracteristics The EPoS I trial randomizes patients with low-risk adenomas into 5 or 10-year surveillance; ; EPoS II randomizes patients with high-risk adenomas into 3 or 5-yearly surveillance ; EPoS III will include patients with serrated polyps in a one-arm study with surveillance after 5 and 10 years. The primary endpoint for all three trials is incidence of colorectal cancer after 10 years of follow-up.

This EPoS trials are the largest in polyp surveillance ever conducted. They address a clinical problem affecting hundreds of thousand individuals in Europe and the US each year, it has a large size, and should thus provide definitive results.

Conditions

Colorectal Neoplasms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

Short-term surveillance

Short-term surveillance. Colonoscopy at 5+10 years in low-risk adenomas or 3+5 years in high-risk adenomas.

Group Type: ACTIVE_COMPARATOR

Colonoscopy

Intervention Type: PROCEDURE

Long-term surveillance

Long-term surveillance. Colonoscopy at 10 years in low-risk adenomas or 5 years in high-risk adenomas.

Group Type: EXPERIMENTAL

Colonoscopy

Intervention Type: PROCEDURE

Interventions

Colonoscopy

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Cecal intubation (preferably documented by images/videoof the apendiceal orifice and the ileocecal valve; but not required).
• Adequate colonic cleansing, with Boston Bowel Cleansing Score equal or higher than 2 points in all colonic segments.
• Complete excision of all polyps at baseline colonoscopy findings (as judged by the trial endoscopists).

Exclusion Criteria

• Lack of consent
• History of CRC or adenomas
• History of serrated polyps ≥ 10 mm in diameter at any colorectal location or ≥ 5 mm if located proximal to the splenic flexure
• Incomplete colonoscopy
• Incomplete endoscopic excision of polyps
• Genetic cancer syndrome (adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome)
• Inflammatory bowel disease
• History of surgical colon resection for any reason
• Severe co-morbidity with reduced life expectancy (NYHA 3-4)
• On-going cytotoxic treatment or radiotherapy for malignant disease
• Long-lasting attention and nursing services (somatic or psychosocial, mental retardation).

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 74 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Asociación Española de Gastroenterología

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rodrigo Jover, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital General Universitario de Alicante

Michael Bretthauer, MD

Role: PRINCIPAL_INVESTIGATOR

University of Oslo

Locations

Hospital General Universitario de Alicante

Alicante, , Spain

Countries

Spain

References

Juul FE, Garborg K, Nesbakken E, Loberg M, Wieszczy P, Cubiella J, Kalager M, Kaminski MF, Erichsen R, Adami HO, Ferlitsch M, Furholm SKB, Zauber AG, Quintero E, Bugajski M, Holme O, Dekker E, Jover R, Bretthauer M. Rates of repeated colonoscopies to clean the colon from low-risk and high-risk adenomas: results from the EPoS trials. Gut. 2023 May;72(5):951-957. doi: 10.1136/gutjnl-2022-327696. Epub 2022 Oct 28.

Reference Type: DERIVED

PMID: 36307178 (View on PubMed)

Jover R, Bretthauer M, Dekker E, Holme O, Kaminski MF, Loberg M, Zauber AG, Hernan MA, Lansdorp-Vogelaar I, Sunde A, McFadden E, Castells A, Regula J, Quintero E, Pellise M, Senore C, Kalager M, Dinis-Ribeiro M, Emilsson L, Ransohoff DF, Hoff G, Adami HO. Rationale and design of the European Polyp Surveillance (EPoS) trials. Endoscopy. 2016 Jun;48(6):571-8. doi: 10.1055/s-0042-104116. Epub 2016 Apr 4.

Reference Type: DERIVED

PMID: 27042931 (View on PubMed)

Other Identifiers

AEG-EPOS-1

Identifier Type: -

Identifier Source: org_study_id